THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

Getting your Trinity Audio player ready... PHILADELPHIA- In the latest blow to Amgen Inc., at least one company that administers Medicare plans has decided to stop paying for the use of the drug ...

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...

Patients with chemotherapy-induced anemia and anemia associated with chronic kidney disease (CKD) will now have access to Amgen's Aranesp, which is a prefilled autoinjector. The product will be ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received interim results from the independent investigator-sponsored “PREPARE†study, an ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa ...

Sometimes no news is good news. That seems to be the case for Amgen Inc., which Thursday disclosed top-line Phase III data showing that Aranesp (darbepoetin alfa) did not raise safety concerns in ...

LOS ANGELES, April 16 (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died ...